As filed with the Securities and Exchange Commission on March 23, 2021

Registration No. 333-            

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

Unity Biotechnology, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

 

 

Delaware

(State or other jurisdiction of

incorporation or organization)

 

2834

(Primary Standard Industrial

Classification Code Number)

26-4726035

(I.R.S. Employer

Identification Number)

 

285 East Grand Avenue
South San Francisco, CA 94080

(650) 614-5220

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

2018 Incentive Award Plan

2018 Employee Stock Purchase Plan

(Full Title of the Plan)

 

Anirvan Ghosh, Ph.D. Chief Executive Officer

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080

(650) 416-1192

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

 

Copy to:

 

Brian J. Cuneo, Esq.

Miles P. Jennings, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Telephone: (650) 328-4600

Facsimile: (650) 463-2600

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.     


 

 


 

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of Each Class of

Securities to be Registered

 

Amount

to be

Registered(1)

 

Proposed

Maximum
Offering Price

Per Share(2)

 

Proposed

Maximum
Aggregate

Offering Price

 

Amount of
Registration Fee

Common Stock, $0.0001 par value per share

 

 2,675,309(3)

 

$6.805

 

$18,205,477.75

 

$1,986.22

Common Stock, $0.0001 par value per share

 

 532,480(4)

 

$6.805

 

$3,623,526.40

 

$395.33

Total:

 

3,207,789

 

$6.805

 

$21,829,004.15

 

$2,381.55

 

 

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the 2018 Incentive Award Plan (the “2018 Plan”) and the 2018 Employee Stock Purchase Plan (the “ESPP”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.

 

(2)

This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrant’s common stock as reported on The Nasdaq Global Select Market on March 19, 2021, which is $6.805.

(3)

Represents (i) 2,662,400 additional shares of common stock available for future issuance under the 2018 Plan resulting from an annual increase as of January 1, 2021 and (ii) 12,909 additional shares of common stock available for future issuance under the 2018 Plan, primarily resulting from repurchases of awards outstanding under the Company’s 2013 Equity Incentive Plan.

 

(4)

Represents the additional shares of common stock available for future issuance under the ESPP resulting from an annual increase as of January 1, 2021.

 

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are exercised and/or vest.  

 

 

 


 


 

EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional  3,207,789 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-224726, 333-230086 and 333-237088) are effective: (i) the 2018 Incentive Award Plan, as a result of (x) the operation of an automatic annual increase provision therein, which added 2,675,309 of common stock, and (y) 12,909 additional shares available under the 2018 Incentive Award Plan, primarily resulting from repurchases of awards outstanding under the Company’s 2013 Equity Incentive Plan, and (ii) the 2018 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 532,480 shares of common stock.  

INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

FORM S-8

 

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 7, 2018 (File No. 333-224726), March 6, 2019 (File No. 333-230086) and March 11, 2020 (File No. 333-237088) are incorporated by reference herein.


 


 

Exhibit Index

 

 

 

 

Incorporated by Reference

 

 

 

 

 

 

 

Filed Herewith

 

Exhibit
Number

 

Exhibit Description

 

Form

 

Date

 

Number

 

 

  4.1

 

Amended and Restated Certificate of Incorporation.

 

8-K

 

5-7-18

 

3.1

 

 

  4.2

 

Amended and Restated Bylaws.

 

8-K

 

5-7-18

 

3.2

 

 

  4.3

 

Form of Common Stock Certificate.

 

S-1/A

 

4-23-18

 

4.2

 

 

  5.1

 

Opinion of Latham & Watkins LLP.

 

 

 

 

 

 

 

X

23.1

 

Consent of Independent Registered Public Accounting Firm.

 

 

 

 

 

 

 

X

23.2

 

Consent of Latham & Watkins LLP (included in Exhibit 5.1).

 

 

 

 

 

 

 

X

24.1

 

Power of Attorney. Reference is made to the signature page to the Registration Statement.

 

 

 

 

 

 

 

X

99.1(a)#

 

2018 Incentive Award Plan.

 

S-8

 

5-7-18

 

99.2(a)

 

 

99.1(b)#

 

Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Incentive Award Plan.

 

S-1

 

4-5-18

 

10.4(b)

 

 

99.1(c)#

 

Form of Restricted Stock Award Grant Notice under the 2018 Incentive Award Plan.

 

S-1

 

4-5-18

 

10.4(c)

 

 

99.1(d)#

 

Form of Restricted Stock Unit Award Grant Notice under the 2018 Incentive Award Plan.

 

S-1

 

4-5-18

 

10.4(d)

 

 

99.2#

 

2018 Employee Stock Purchase Plan.

 

S-8

 

5-7-18

 

99.3

 

 

 

# Indicates management contract or compensatory plan.

 


 


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California.

 

 

Unity Biotechnology, Inc.

 

 

 

Date: March 23, 2021

By:

 

/s/ Anirvan Ghosh

 

 

 

Anirvan Ghosh, Ph.D.

Chief Executive Officer

 

 

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Anirvan Ghosh, Ph.D., Alexander Nguyen, and Lynne Sullivan, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the Registrant, in the capacities and on the dates indicated.

 

 

Signature

 

Title

 

Date

 

 

 

/s/ Anirvan Ghosh

Anirvan Ghosh, Ph.D.

 

Chief Executive Officer and Director

(Principal Executive Officer)

 

March 23, 2021

 

 

 

/s/ Lynne Sullivan

Lynne Sullivan

 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

March 23, 2021

/s/ Keith R. Leonard Jr.

Keith R. Leonard Jr.

 

Chairman

 

 

March 23, 2021

 

 

 

/s/ Paul L. Berns

Paul L. Berns

 

Director

 

March 23, 2021

 

 

 

/s/ Kristina M. Burow

Kristina M. Burow

 

Director

 

March 23, 2021

 

 

 

/s/ Graham K. Cooper

Graham K. Cooper

 

Director

 

March 23, 2021

 

 

 

/s/ Nathaniel E. David

Nathaniel E. David, Ph.D.

 

Director

 

March 23, 2021

 

 

 

 

 

 

 


 

/s/ Gilmore ONeill

Director

March 23, 2021

Gilmore O’Neill, M.B.

 

 

 

/s/ Margo Roberts

Director

March 23, 2021

Margo Roberts, Ph.D.

 

 

 

/s/ Camille D. Samuels

Camille D. Samuels

 

Director

 

March 23, 2021

 

 

UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more UNITY Biotechnology Charts.
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more UNITY Biotechnology Charts.